Clareon® PanOptix® Pro
Discover More Light Utilization
with Less Light Scatter1,3*
*PanOptix® has 88% light utilization (12% scatter light)
PanOptix® Pro has 94% light utilization (6% scatter light).
Clareon® PanOptix® Pro
Discover More Light Utilization with Less Light Scatter1,3*
*PanOptix® has 88% light utilization (12% scatter light)
PanOptix® Pro has 94% light utilization (6% scatter light).
Everything You Love About Clareon® PanOptix®,
Now With Half the Light Scatter1,2*
With ENLIGHTEN® NXT Optical Technology, PanOptix® Pro now offers:
• 50% less light scatter by harnessing 94% of total light energy1,2†
• The lowest light scatter of any trifocal IOL1,8**,††
• Uninterrupted light distribution across the full visual range1§
*Compared to Clareon® PanOptix®.
**Based on manufacturer reported values and respective methodology for trifocal IOLs including Clareon® PanOptix®, Envista Envy^, AT Elana^ (not available in the US), Gemetric^ and Rayner^. †Compared to Clareon® PanOptix®. PanOptix® has 88% light utilization (12% scatter light)/PanOptix® Pro 94% light utilization (6% scatter light).
††Based on bench and vision simulator studies.
§Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic
^Trademarks are property of their respective owners.
The lowest light scatter of any trifocal IOL1-8*,**
*Based on bench and vision simulator studies.
**Based on manufacturer reported values and respective methodology for trifocal IOLs including Clareon® PanOptix®, Envista Envy^, AT Elana^, Gemetric^ and Rayner^.
^Trademarks are property of their respective owners.
Elevating What’s Possible In PCIOLs
With ENLIGHTEN® NXT Optical Technology
Unprecedented 94% light utilization* like no other trifocal IOL.1,3,4-8**
With ENLIGHTEN® NXT Optical Technology, PanOptix® Pro now offers:
- 50% less light scatter by harnessing 94% of total light energy1,2†
- The lowest light scatter of any trifocal IOL1,8**,††
- Uninterrupted light distribution across the full visual range1§
*Compared to Clareon® PanOptix®.
**Based on manufacturer reported values and respective methodology for trifocal IOLs including Clareon® PanOptix®, Envista Envy^, AT Elana^ (not available in the US), Gemetric^ and Rayner^.
†Compared to Clareon® PanOptix®. PanOptix® has 88% light utilization (12% scatter light)/PanOptix® Pro 94% light utilization (6% scatter light).
††Based on bench and vision simulator studies.
§Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic
^Trademarks are property of their respective owners.
Designed for Better Image Contrast1*
Minimize Visual Disturbances
Built on the clinically proven visual disturbance profile of world-leading PanOptix®
Starburst
Only 2.6% of patients
were bothered very much by starburst9*
(n=220)
Halo
Only 1.4% of patients
were bothered very
much by halo9*
(n=222)
Glare
Only 0.8% of patients
were bothered very
much by glare9*
(n=221)
*Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome” and "severe" visual disturbances. Clinical studies were performed on the AcrySof® IQ PanOptix® IOL; AcrySof® IQ PanOptix® and Clareon® PanOptix® are optically equivalent.
Outstanding Spectacle Independence
- True comfort at intermediate distance10-13
- High quality near vision up to the very close distance of 33 cm10*
- Freedom from glasses even in low light14**†
*Based on data for AcrySof® IQ PanOptix® Trifocal IOL
**All-implanted analysis set.
†In response to the IOLSAT questionnaire question “In the past 7 days, how often did you need to wear eyeglasses to see”?
Undeniable Patient Satisfaction
- PanOptix® is a trusted choice
- 99.2% of PanOptix® patients would have the same lens implanted again15*
- 98.4% of PanOptix® patients would recommend the lens to a friend15**
*Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127
**Response to the following question on IOLSAT questionnaire at 6 months post-op "Given your vision today, would you recommend the lenses you had implanted to your family or friends?"; n=127.
Explore additional resources for Clareon® PanOptix® Pro IOLs
Are you ready to level up
to the Power of Pro?1,3*
*Compared to Clareon® PanOptix®, based on increased light utilization of 88% to 94%.
Are you ready to level up to the Power of Pro?1,3*
*Compared to Clareon® PanOptix®, based on increased light utilization of 88% to 94%.
Frequently Asked Questions About
Trifocal Intraocular Lenses
Clareon® PanOptix® Pro incorporates ENLIGHTEN® NXT Optical Technology, designed to deliver 94% light utilization¹ and reduced light scatter compared to the prior platform². The trifocal focal distribution remains consistent while optical efficiency is optimized.
Clareon® PanOptix® Pro incorporates ENLIGHTEN® NXT Optical Technology designed to optimize light transmission through the diffractive optic, resulting in 94% total light utilization¹ and reduced light scatter compared to the prior platform².
Lower light scatter may contribute to improved retinal image quality and enhanced contrast performance³, which are clinically relevant considerations in trifocal IOL selection.
As with trifocal IOLs, patients may report visual phenomena such as halos or glare, particularly in low-light conditions. Clareon® PanOptix® Pro is designed to help minimize visual disturbances² and is designed to improve the image contrast compared to the prior platform1.
Appropriate patient selection and expectation setting remain essential, and published clinical outcomes for the PanOptix® platform support high levels of patient satisfaction in appropriately selected patients⁴.
Clareon® PanOptix® Pro is designed to improve the image contrast compared to the prior platform.1
These improvements are associated with optimized light distribution and reduced light scatter within the diffractive optic.16 Contrast performance is a key consideration when evaluating trifocal IOLs, particularly in mesopic conditions.
Yes, both Clareon PanOptix Pro and Clareon PanOptix have the same a-constant, and surgeons who have an optimized a-constant for Clareon PanOptix can leverage it for Clareon PanOptix Pro.15
• ¹ corresponds to the 94% light utilization claim shown in the image
• ² corresponds to lowest light scatter / visual disturbance claims
• ³ corresponds to contrast improvement data (+16%, +4%)
• ⁴ corresponds to patient satisfaction section
***Refer to references and numbering from the bottom of the in development PanOptix Pro ECP product page
References
1. Alcon data on file, 2025. REF-25218.
2. Alcon data on file, 2015. REF-08546.
3. Kohnen T, Herzog M, Hemkeppler E, et al. Visual performance of a quadrifocal (trifocal) intraocular lens following removal of the crystalline lens. Am J Ophthalmol. 2017;184:52-62. doi:10.1016/j.ajo.2017.09.016
4. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston.
5. Rayner Professional Website. https://rayner.com/en/iol/trifocal/rayone-trifocal/. Accessed September 2024.
6. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53.
7. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014.
8. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; https://europe.ophthalmologytimes.com/zeiss- cataract-insight-series?page=1 Accessed December 2024.
9. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
10. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234
11. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965
12. Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. https://www.ccohs.ca/oshanswers/ergonomics/office/.
13. Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/j.jcrs.0000000000000780
14. Alcon data on file, 2018. REF-01475
15. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021.
16. Alcon Data on File, 2024. REF-25903
Please refer to the product operator manual or product directions for use for a full list of indications, contraindications and warnings. Available at ifu.alcon.com
